Tenderwize
Retour à la recherche

Pharmaceutical product with active ingredient Aripiprazole (ATC: N05AX12 - for parenteral administration)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 214 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Aripiprazol (ATC: N05AX12 - für die parenterale Applikation)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

15 / 100

Facteurs de risque

The buyer may terminate contracts if exclusive contracts for the same active ingredient are later tendered during the c...

No estimated value or minimum volume is provided, making it impossible to assess potential revenue.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for pharmaceutical products with Aripiprazole (parenteral application) under an open-house model.
  • Any qualified pharmaceutical company can conclude a contract at any time under uniform conditions.
Afficher le résumé complet

This is a notice for non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for pharmaceutical products containing Aripiprazole (ATC: N05AX12, parenteral application) issued by AOK Sachsen-Anhalt. The procurement follows an 'open-house model' allowing any qualified pharmaceutical company to join at any time during the contract period (01.06.2025 to 31.05.2027). The tender is explicitly not a public procurement under EU law but published for transparency. No estimated value or award criteria are specified; all eligible companies get a contract without competition. The deadline for submission is 31.03.2027, with contracts starting as early as 01.06.2025.

Risques

The buyer may terminate contracts if exclusive contracts for the same active ingredient are later tendered during the c...

No estimated value or minimum volume is provided, making it impossible to assess potential revenue.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or a group of pharmaceutical companies.

Administrative

  • Must complete and sign the participation documents.
  • Electronic submission allowed only via qualified electronic signature (eIDAS Regulation) to [email protected].

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Pharmaceutical product with active ingredient Aripiprazole (ATC: N05AX12 - for parenteral administration)

Non-exclusive discount agreements for finished medicinal products with Aripiprazole (parenteral). The contract is open to all qualifying pharmaceutical companies at any time. No exclusivity; contracts end on 31.05.2027 regardless of start date. The buyer may terminate if exclusive contracts are later tendered.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 30, 2027

Détails de la procédure

Date de publication
09 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
232943-2025

Documents (1)

Appels d'offres similaires